Pulmonary complications of HIV infection: Report of the fourth NHLBI workshop

American Journal of Respiratory and Critical Care Medicine

Volumn 164, Issue 11, 2001, Pages 2120-2126

  Beck, James M ^a,b,c,d   Rosen, Mark J ^a,b,c   Peavy, Hannah H ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b BETH ISRAEL MEDICAL CENTER   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

BACTERIAL PNEUMONIA; CLINICAL FEATURE; CONFERENCE PAPER; EMPHYSEMA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KAPOSI SARCOMA; LUNG INFECTION; PNEUMOCYSTIS CARINII; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; TUBERCULOSIS; VIRUS PNEUMONIA;

EID: 0035666246     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.164.11.2102047     Document Type: Conference Paper

References (62)

1. Pulmonary complications of the acquired immunodeficiency syndrome: Report of a National Heart, Lung, and Blood Institute Workshop
2. Pulmonary complications of the acquired immunodeficiency syndrom: An update. Report of the second National Heart, Lung, and Blood Institute workshop
3. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997
4. HIV and AIDS - United States, 1981-2000
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. The AIDS epidemic - Considerations for the 21st century
7. HIV/AIDS Surveillance Report
8. HIV-1, cytokines, and the lung
9. CD4 receptor-dependent entry of human immunodeficiency virus type-1 env-pseudo-types into CCR5-, CCR3-, and CXCR4-expressing human alveolar macrophages is preferentially mediated by the CCR5 coreceptor
10. Patterns of chemokine receptor fusion cofactor utilization by human immunodeficiency virus type 1 variants from the lungs and blood
11. Immunology of interstitial lung diseases: Cellular events taking place in the lung of sarcoidosis, hypersensitivity pneumonitis and HIV infection
12. CD8 T-cell infiltration in extravascular tissues of patients with human immunodeficiency virus infection. Interleukin-15 upmodulates costimulatory pathways involved in the antigen-presenting cells-T-cell interaction
13. Impaired IgG production in the lungs of HIV-infected individuals
14. + cell count. A randomized, double-blind, placebo-controlled trial
15. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
16. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons
17. Drug interactions of antiretroviral agents
18. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy
19. HAART-associated body habitus and metabolic changes, Part 2
20. + T cell homeostasis and function in advanced HIV disease
21. Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy
22. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS
23. Continuous axenic cultivation of Pneumocystis carinii
24. Pneumocystis carinii: Antigenic, immunological, and molecular characterization
25. Immunological features of Pneumocystis carinii infection in humans
26. Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice
27. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes
28. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia
29. + lymphocytes in host defense against Pneumocystis carinii in mice
30. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung
31. A TH1→TH2 switch is a critical step in the etiology of HIV infection
32. Cytokines and pulmonary infection with Pneumocystis carinii
33. + T cells
34. P. carinii induces selective alterations in component expression and biophysical activity of lung surfactant
35. Surfactant protein-A reduces binding and phagocytosis of Pneumocystis carinii by human alveolar macrophages in vitro
36. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages
37. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study
38. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection
39. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy
40. The relation between physician experience and patterns of care for patients with AIDS-related Pneumocystis carinii pneumonia: Results from a survey of 1,500 physicians in the United States
41. Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples
42. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia
43. Tuberculosis, AIDS, and death among substance abusers on welfare in New York City
44. A prospective study of tuberculosis and HIV disease progression
45. Does the onset of tuberculosis in AIDS predict shorter survival? Results of a cohort study in 17 European countries over 13 years
46. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: An international randomized trial
47. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations
48. Bacterial pneumonia in patients with HIV infection
49. Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression
50. Cytomegalovirus pneumonia in AIDS patients: Value of cytomegalovirus culture from BAL fluid and correlation with lung disease
51. Endemic mycosis complicating human immunodeficiency virus infection
52. Fungal infection in HIV-infected persons
53. Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort
54. Bacterial bronchitis and bronchiectasis in human immunodeficiency virus infection
55. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers
56. Association of cancer with AIDS-related immunosuppression in adults
57. Human herpesvirus 8 seropositivity risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases
58. Diagnosis of pulmonary Kaposi's sarcoma by detection of human herpes virus 8 in bronchoalveolar lavage
59. Primary effusional lymphoma: A new non-Hodgkin's lymphoma entity
60. Alterations in cardiac and pulmonary function in pediatric rapid human immunodeficiency virus type 1 disease progressors
61. Design of a prospective study of the pulmonary complications of human immunodeficiency virus infection